NSAIDs linked to decreased breast cancer recurrence among obese women
the ONA take:
According to findings published in the journal Cancer Research, overweight or obese women who take non-steroidal anti-inflammatory drugs (NSAIDs) have a reduced risk of breast cancer recurrence.
The researchers analyzed data from 440 women, most of whom were overweight or obese and post-menopausal, with estrogen-driven breast cancer treated between 1987 and 2011. They found that approximately 6% of women who said they took NSAIDs regularly experienced a relapse of their breast cancer compared with 12% of women who did not take NSAIDs regularly.
Senior researcher Linda deGraffenried, PhD, of The University of Texas in Austin, Texas was surprised that they found such a dramatic result. In addition, cancers that recurred in women who regularly took NSAIDs reappeared later than those did not report regular NSAID use.
The researchers wanted to find an explanation for the association, and so by utilizing lab experiments and blood samples from overweight women, they found that by reducing inflammation, NSAIDs make the environment of their bodies more similar to a woman of normal body weight. This change makes their cancer more susceptible to treatment.
Further studies must be conducted before NSAIDs are recommended for all obese women with estrogen-driven breast cancer. NSAIDs carry increased cardiovascular, gastrointestinal, and renal risks.
In overweight women, aspirin or other drugs might make certain breast cancers more treatable.
In overweight women, aspirin or other drugs that reduce inflammation might make certain breast cancers more treatable, researchers suggest.
Hormone-driven breast cancer was less likely to return in overweight women who regularly used anti-inflammatory medicines, they found. But their findings don't prove the drugs prevent cancer and it's too soon to tell women to start taking them to protect against cancer recurrence, the researchers warn.
Still, senior researcher Linda deGraffenried of The University of Texas in Austin told Reuters Health said, “I was probably as surprised as anyone that we found such a dramatic effect that we did.”
She and her colleagues write in the journal Cancer Research that in past studies, breast cancer outcomes tended to be worse in obese women than in thinner women.
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors
- Directly Informing Patients of Breast Cancer Risk, Options Improves Follow-Up Screening
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Mortality Rates Highest Among Youngest Oncology Patients, Particularly Minorities
- Survey Reveals Research Priorities for Cancer Patients, Oncology Nurses
- Smoking Increases Long-Term Risks From Radiotherapy in Breast Cancer
- Free Lung Cancer Screening Findings Support Continual Screenings in High-Risk Populations
- Parental Self-persuasion in Low-Income Groups Improves HPV Vaccination Rates
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|